This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (16)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

ROBERT R. KIERLAND, M.D.; LOUIS A. BRUNSTING, M.D.; PAUL A. O'LEARY, M.D.

AMA Arch Derm Syphilol. 1953;68(6):651-663.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

IN A PRELIMINARY report¹ we indicated that quinacrine hydrochloride (atabrine) has a definite place in the treatment of patients with lupus erythematosus—especially in those with the chronic discoid variety. We wish now to report on our additional experience and longer observation of the patients treated.

Apparently the English-speaking world first became aware of the value of quinacrine in the treatment of patients with lupus erythematosus from the report of Page,² although such therapy had been described 10 years earlier by Prokoptchouk,³ Sorinson,⁴ Popoff and Kutintscheff,⁵ and Ottolenghi and Lodigiani.⁶ During the past year the case presentations at society meetings and a few reports in the literature^* indicate general agreement that quinacrine is an efficient drug for the treatment of chronic discoid lupus erythematosus.

Prokoptchouk³ successfully treated 35 patients with lupus erythematosus by giving 100 mg. of quinacrine hydrochloride three times daily . . . [Full Text PDF of this Article]

Author Affiliations
ROCHESTER, MINN.

From the Section of Dermatology, Mayo Clinic.

Footnotes
Read at the Seventy-Third Annual Meeting of the American Dermatological Association, Inc., Lake Placid, N. Y., June 11, 1953.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?